High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 839-847

  Oyan, Basak ^a   Koc, Yener ^a   Ozdemir, Evren ^b   Kars, Ayse ^b   Turker, Alev ^b   Tekuzman, Gulten ^b   Kansu, Emin ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Autologous; Multiple myeloma; Non myeloablative; Thalidomide; Transplantation

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERFERON; LEVOFLOXACIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE; VALACICLOVIR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PYRAZINE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIZZINESS; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HLA MATCHING; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; SIBLING; SOMNOLENCE; STEM CELL MOBILIZATION; SURVIVAL TIME; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MORTALITY; PROCEDURES; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 71149109512     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00950.x     Document Type: Article

References (34)

1. Child JA, Morgan GJ, Davies FE. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875.
2. Blade J, Vesole DH, Gertz M. Transplantation for multiple myeloma: who, when, how often? High-dose therapy in multiple myeloma. Blood 2003, 102:3469.
3. Vesole DH. Transplantation for multiple myeloma: who, when, how often? Patient selection and goals. Blood 2003, 102:3471.
4. Gertz M. Transplantation for multiple myeloma: who, when, how often? Pertinent questions. Blood 2003, 102:3472.
5. Badros A, Barlogie B, Morris C. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97:2574.
6. Badros A, Barlogie B, Siegel E. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002, 20:1295.
7. Giralt S, Thall PF, Khouri I. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631.
8. Attal M, Harousseau JL, Stoppa AM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91.
9. Alexanian R, Weber D, Giralt S. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001, 27:1037.
10. Blade J, San Miguel JF, Fontanillas M. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996, 14:2167.
11. Blade J, Samson D, Reece D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115.
12. Barlogie B, Jagannath S, Desikan KR. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55.
13. Vesole DH, Tricot G, Jagannath S. Autotransplants in multiple myeloma: what have we learned?. Blood 1996, 88:838.
14. Desikan R, Barlogie B, Sawyer J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000, 95:4008.
15. Barlogie B, Jagannath S, Vesole DH. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789.
16. Attal M, Harousseau J, Facon T. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the " Intergroupe Francophone du Myeloma" (IFM 94) [abstract]. Blood 2002, 100:5a.
17. Segeren CM, Sonneveld P, van der Holt B. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003, 101:2144.
18. Kroger N, Sayer HG, Schwerdtfeger R. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100:3919.
19. Kroger N, Schwerdtfeger R, Kiehl M. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755.
20. Maloney DG, Molina AJ, Sahebi F. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447.
21. Przepiorka D, Weisdorf D, Martin P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825.
22. Sullivan KM, Agura E, Anasetti C. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991, 28:250.
23. Kaplan EJ, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457.
24. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972, 135:185.
25. Crawley C, Lalancette M, Szydlo R. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532.
26. Alexanian R, Haut A, Khan AU. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208:1680.
27. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310:1353.
28. Samson D, Gaminara E, Newland A. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989, 2:882.
29. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887.
30. Rajkumar SV, Hayman S, Gertz MA. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319.
31. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003, 21:16.
32. Harousseau J, Attal M, Leleu X. Bortezomib (VELCADE) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]. Blood 2004, 104:98a.
33. Wang LM, Weber D, Delasalle KB, Alexanian R. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood 2004, 104:64a.
34. Reichardt VL, Okada CY, Liso A. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999, 93:2411.